Free tool
Drug literature search
Last checked: Nov 20, 2026Source: PubMed, Europe PMC, OpenAlex
1,872 results in Europe PMC
PubMed plus preprints and full-text open access papers. Showing the first 25. Limited to clinical trials, meta-analyses and systematic reviews.
- GLP-1-based therapies for reduction of heart failure and cardiovascular outcomes: A systematic review and meta-analysis of randomized controlled trials.
Sajid EU, Ali T, Azeem B, Hassan D, Waqar M, Rayyan Ahmed S, Ahmed Meenai E, A Abu Elainein M, Soomro I, Hasnain Azeem M, Ramalingam A, Bawa D, Baig M, Fakih N, J Saldanha I. · Medicine (Baltimore) · 2026 · cited 0 timesOpen accessmeta-analysis, systematic review
- Efficacy of sodium-glucose cotransporter 2 inhibitors after acute myocardial infarction: Are the benefits limited to patients with diabetes? A systematic review and meta-analysis.
Santos MCF, Mamede I, Bessa R, Carvalhal G, Leão LA, Pinto M. · J Diabetes Complications · 2026 · cited 0 timesmeta-analysis, systematic review
- Are SGLT2 inhibitors really associated with increased urinary tract infection risk? A trial-level meta-analysis across type 2 diabetes, heart failure, and chronic kidney disease.
Matteucci A, Di Fusco SA, Bonanni M, Castello L, Aquilani S, Fedele S, Nardi F, Colivicchi F. · Daru · 2026 · cited 2 timesmeta-analysis, systematic review
- Combined use of SGLT2 inhibitor and GLP-1 receptor agonist versus either monotherapy for cardiorenal Outcomes: an exploratory network meta-analysis of 16 randomized trials.
Banerjee M, Basu M, Mukhopadhyay P, Ghosh S. · Endocrine · 2026 · cited 0 timessystematic review, network meta-analysis
- SGLT2 inhibitors and secondary polycythemia: a systematic review and meta-analysis of hematologic effects in patients with type 2 diabetes.
Ali EAH, Rabadi M, Aweer RA, Subahi E, Abdelmahmuod EA, Alshurafa A, Abdulgayoom M, Mudarres MF, Elshaikh U, Al-Mashdali A, Mohamed S. · Eur J Clin Pharmacol · 2026 · cited 0 timesOpen accessmeta-analysis, systematic review
- Adverse Effects of Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors in Pediatric Heart Failure: A Systematic Review and Meta-Analysis of Proportions.
Cakan B, Ardali A, Odemis E. · Paediatr Drugs · 2026 · cited 0 timessystematic review
- "In-Hospital Initiation of SGLT-2 Inhibitors in Acute Heart Failure: A Systematic Review and Meta-Analysis of Clinical, Decongestion, and Safety Outcomes".
Ahmed HM, Rehman UU, Owais M. · Cardiovasc Drugs Ther · 2026 · cited 1 timesmeta-analysis, systematic review
- Efficacy of sodium-glucose cotransporter-2 inhibitors on functional mitral regurgitation associated with heart failure: a systematic review and meta-analysis of randomized controlled trials.
Kajo C, Alaraibi AJ, Almutairi OT, Alaraibi YH, Alibrahim A, Almutawah YKA, Alasfar SWS, Ali MW, Hajjiri A, Alqaryuti M, Alfehaid A, Arekat D. · Front Cardiovasc Med · 2026 · cited 0 timesOpen accesssystematic review, systematic-review
- Renoprotective effects and safety of sodium-glucose cotransporter 2 inhibitors in diabetic chronic kidney disease: A systematic review and meta-analysis.
Shi X, Fu K, Hu M, Li R, Li H, Xu S. · Medicine (Baltimore) · 2026 · cited 0 timesOpen accessmeta-analysis, systematic review
- Renal and cardiovascular outcomes and safety of SGLT2 inhibitors in patients aged ≥ 65 years with non-dialysis chronic kidney disease: a systematic review and meta-analysis of subgroup-level estimates derived from randomized trials.
Bao Z, Hu J, Sun Y, Li X, Lin R, Zhu C, Yin J. · BMC Cardiovasc Disord · 2026 · cited 0 timesOpen accessmeta-analysis, systematic review
- Incremental effects of SGLT2 inhibitors, GLP-1 receptor agonists, and pioglitazone in type 2 diabetes and MASLD across Asian study settings: a systematic review and meta-analysis.
Zheng H, Han J. · Front Endocrinol (Lausanne) · 2026 · cited 0 timesOpen accessmeta-analysis, systematic review
- SGLT2 inhibitors and cardiorenal outcomes across operationally mapped cardiovascular-kidney-metabolic syndrome stages 2-3 and stage 4: a systematic review and meta-analysis.
Sun S, Guo Y, Wu H, Wang X, Ji X, Xue X, Liu H. · BMC Endocr Disord · 2026 · cited 0 timesmeta-analysis, im
- Glucose cotransporter-2 inhibitors on mortality and hospitalization in heart failure patients: a comprehensive meta-analysis.
Mao X, Liu W, Hu B, Xu E. · Front Endocrinol (Lausanne) · 2026 · cited 1 timesOpen accessmeta-analysis, systematic review
- Therapeutic impact of SGLT2 inhibitors following transcatheter aortic valve implantation: a grade-assessed systematic review and meta-analysis.
Hamzah KA, Kurmasha YH, Al-Shammari AS, Shweliya MA, Al-Janabi AAH, Shahzaib M, Akoum A, Sattar Y. · Eur J Clin Pharmacol · 2026 · cited 4 timesmeta-analysis, systematic review
- Efficacy of ARNIs on hard renal outcomes in heart failure with and without chronic kidney disease: when endpoint definition matters-an updated meta-analysis.
Cianciolo G, Vetrano D, Tomassetti A, Tringali E, Iacoviello M, Marazia S, Fucili A, La Manna G, De Pascalis A. · ESC Heart Fail · 2026 · cited 0 timesOpen accesseditorial, meta-analysis
- Effectiveness of SGLT2 inhibitors in slowing chronic kidney disease progression and reducing mortality: a meta-analysis.
Sharma A, Sharma B, Vamaraju DS, Ajay AK. · Front Pharmacol · 2026 · cited 0 timesOpen accesssystematic review, systematic-review
- Network and pairwise meta-analysis of the effects of novel hypoglycemic agents on cardiorenal outcomes in patients with type 2 diabetes and heart failure.
Ye X, Wu Q, Li L, Huang M, Wang S. · Front Endocrinol (Lausanne) · 2026 · cited 0 timesOpen accesssystematic review, systematic-review
- The impact of SGLT2 inhibitors on renal outcomes in patients with type 2 diabetes and chronic kidney disease: systematic review and meta-analysis.
Su Y, Wang W, Li H. · Front Endocrinol (Lausanne) · 2026 · cited 0 timesOpen accessmeta-analysis, systematic review
- Effect of sodium-glucose cotransporter-2 inhibitors on haemoglobin and haematocrit levels in heart failure: a systematic review and meta-analysis.
Armani Moghadam S, Shahmohammadi A, Salehi K, Narimani-Javid R, Soltani P, Zafarmandi S, Shafieyoun MH, Mahalleh M, Ahmed R, Bekfani T, Biering-Sørensen T, Hosseini K. · ESC Heart Fail · 2026 · cited 1 timesOpen accessmeta-analysis, systematic review
- Efficacy and Safety of GLP-1 Receptor Agonists on Combined Cardiovascular and Renal Outcomes in Patients With Chronic Kidney Disease: A Systematic Review and Meta-Analysis.
Kaur R, Singh A. · Diabetes Obes Metab · 2026 · cited 1 timessystematic review, network meta-analysis
- Combination Therapy of GLP-1 RA and SGLT2i in Patients with Established Heart Failure: A Systematic Review and Meta-Analysis of Observational Studies.
Tristan CD, Irnizarifka I, Kynaya EM, Gani M, Wijayanto MA, Asrial AA, Pranata R. · Am J Cardiovasc Drugs · 2026 · cited 0 timesmeta-analysis, systematic review
- A 52-Week Efficacy and Safety Study of Teneligliptin, as an Add-On to Empagliflozin and Metformin in Patients With Type 2 Diabetes Mellitus: A Randomised, Double-Blind, Placebo-Controlled Phase 3 Trial (TERA305 Study).
Moon JS, Han KA, Kim DL, Kim SY, Kim SK, Ku BJ, Lee WJ, Oh TK, Seo JA, Chang SA, Lee MK, Ahn KJ, Kim CS, Kim TN, Cha BS. · Diabetes Obes Metab · 2026 · cited 0 timesOpen accessclinical trial, phase iii, multicenter study
- From cancer safety signals to cardio-oncology translation: a dual-database bibliometric and BERTopic semantic analysis of SGLT2 inhibitor research in oncology (2014-2026).
Tang X, Niu W, Lan Z, Zhong Z. · Front Oncol · 2026 · cited 0 timesOpen accesssystematic review, systematic-review
- SGLT2 inhibitors are associated with reductions in epicardial adipose tissue volume and thickness: a meta-analysis.
Khanna S, Kalman E, Thungathurthi K, Thakur U, Vasanthakumar S, Virk S, Bhat A, Lin A, Arnott C, Nerlekar N. · Int J Obes (Lond) · 2026 · cited 1 timesOpen accessmeta-analysis, systematic review
- The Effects of Combined Antihypertensive and Antidiabetic Therapies on Cardiovascular Outcomes: A Systematic Review and Meta-Analysis.
Hsieh WC, Henry BM, Édes I. · Diabetes Obes Metab · 2026 · cited 1 timesOpen accessmeta-analysis, systematic review
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.